Brief: SOBI's Tryngolza Cuts Pancreatitis Risk By 85% In Study
26/05/2026 15:18
BRIEF-SOBI's Tryngolza Cuts Pancreatitis Risk By 85% In Study May 26 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:
TRYNGOLZA REDUCES ACUTE PANCREATITIS RISK BY 85% AND TRIGLYCERIDES BY 66% AFTER SIX MONTHS
Source text: ID:nWkr8wbfKb
Further company coverage: SOBIV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Swedish Orphan Biovitrum AB (publ)
See all newsTop of the Street: SOBI, Sonova, BAT, Imperial Brands
SOBI slips after Ionis lowers Tryngolza sales forecast
Brief: Swedish Orphan Biovitrum Executive Sells, Buys Shares
Europe Research Roundup: Centrica, Fuchs, URW
Brief: Swedish Orphan Biovitrum Proposes Börje Ekholm As New Chair And Board Member At 2027 AGM